102 related articles for article (PubMed ID: 38715329)
1. Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
Sotoudeheian M
Protein Pept Lett; 2024 May; ():. PubMed ID: 38715329
[TBL] [Abstract][Full Text] [Related]
2. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
4. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
7. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
10. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
11. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
13. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease.
Zhu C; Huang D; Ma H; Qian C; You H; Bu L; Qu S
Front Endocrinol (Lausanne); 2022; 13():848937. PubMed ID: 35620390
[TBL] [Abstract][Full Text] [Related]
14. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
15. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
16. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
17. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
18. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
[TBL] [Abstract][Full Text] [Related]
19. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
Ismaiel A; Dumitrascu DL
Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis.
Méndez-Sánchez N; Córdova-Gallardo J; Barranco-Fragoso B; Eslam M
Front Immunol; 2021; 12():641240. PubMed ID: 33833761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]